Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%.
A group of 16 advocacy groups are urging HHS to make zero co-pays for biologics a part of its prescription drug price reform program.
As the deadline approaches for HHS to divulge its game plan for controlling prescription drug costs and “price gouging,” levels of concern are rising among providers and manufacturers.
A group of 16 patient advocacy organizations has asked CMS and HHS to consider establishing a zero co-pay policy for Medicare Part B patients, a move the groups said would improve access to biosimilars and save seniors in Medicare as much as $3 billion in out-of-pocket costs.
“Alignment of incentives across Medicare programs that encourage the use of biosimilars are integral to the development of the US market, leading to increased biosimilar usage and unlocking immense savings in the US health care system,” the group said in an open letter to HHS and CMS officials.
The letter was signed by the Allergy & Asthma Network, CancerCare, Consumer Action, Crohn’s & Colitis Foundation, Endocrine Society, Healthy Women,, International Myeloma Foundation, Lupus Foundation of America, and others.
President Biden has directed HHS to produce a policy for combating high prescription drug prices as soon as Monday, August 23.
The advocacy groups, in their letter, acknowledge the high cost of biologics, which are made from living organisms and require extensive, carefully controlled processes to develop and manufacture.
Biosimilars are lower-cost alternatives to originator biologics and have no clinically meaningful differences when it comes to safety or efficacy, according to the FDA. “These therapies represent an opportunity to improve the health and well-being of millions of Americans and, at the same time, save US taxpayers billions in health care costs," the advocacy groups said.
Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%.
US patients have had access to biosimilars for 6 years; 30 of them are now approved and 21 are on the market. Medicare “enrollees can face thousands of dollars in annual out-of-pocket costs for biologics, creating affordability and access barriers for patients in Part B. Nearly 15% of Medicare Part B enrollees pay the full 20% coinsurance for their reference biologic, while others have supplemental insurance that only covers a portion of the 20%,” the letter states.
The group estimates that a zero co-pay policy would save taxpayers $5 billion over 10 years.
Other signatories to the letter included Beyond Type 1, DiabetesSisters, National Consumers League, Patients Rising Now, Rheumatology Nurses Society, Sjögren’s Foundation, and ZERO - The End of Prostate Cancer.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.